. 2020 Jun 10;59(12):3858–3868. doi: 10.1093/rheumatology/keaa072

Table 2.

Primary efficacy analysis: absolute change in WOMAC pain score

	Diacerein	Celecoxib	P-value	Treatment differences
Primary analysis
PP	(n = 140)	(n = 148)
	−11.1 (0.9)^a	−11.8 (0.9)^a	0.597^b	0.7 (−1.8, 3.2)^c
Supportive analysis
ITT	(n = 183)	(n = 187)
	−9.6 (0.8)^a	−10.0 (0.8)^a	0.712^b	0.4 (−1.9, 2.7)^c
ITT (LOCF)^d	(n = 183)	(n = 187)
	−9.5 (0.8)^a	−10.0 (0.8)^a	0.657^b	0.5 (−1.7, 2.8)^c

WOMAC pain score scale 0–50.

Absolute change from baseline to day 182, MMRM model adjusted mean (s.e.).

MMRM model, P-value of treatment effect.

MMRM model adjusted means (95% CI).

MMRM model where missing data were imputed by the LOCF approach.

ITT: intention-to-treat; LOCF: last observation carried forward; MMRM: mixed models for repeated measurement; n: number of patients in the treatment group; PP: per protocol; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.